z-logo
Premium
Purkinje cell survival in organotypic cultures: Implication of Rho and its downstream effector ROCK
Author(s) -
Julien Sylvie,
Schnichels Sven,
Teng Henry,
Tassew Nardos,
HenkeFahle Sigrid,
Mueller Bernhard K.,
Monnier Philippe P.
Publication year - 2007
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.21511
Subject(s) - effector , intracellular , microbiology and biotechnology , biology , purkinje cell , programmed cell death , cell , apoptosis , cell culture , cerebellum , chemistry , biochemistry , neuroscience , genetics
Organotypic cultures of postnatal day 1 (P1) to P7 mouse cerebella are well‐established models for studying cell survival. In the present work, we investigate the involvement of the Rho/ROCK intracellular pathway in Purkinje cell survival by using organotypic cultures of P3 Swiss mice. Specific inhibitors of Rho or ROCK were applied at different concentrations to the slice cultures, which were maintained for 5 days in vitro. We show that the bacterial exoenzyme C3 transferase, a specific inhibitor of the small GTPase Rho, increases Purkinje cell survival. There is a 4.5‐ and 2.5‐fold increase in Purkinje cell survival when C3 intracellular uptake is promoted either by the PEP‐1 peptide or by the C2IN carrier protein, respectively, and not with the commonly used TAT peptide. Moreover, treatment with Y27632 and H‐1152, two specific inhibitors of the Rho kinase ROCK, also strongly reduces apoptotic cell death and results in 6.5‐ and 8.5‐fold increases in cell survival, respectively. In immunohistochemical analysis, we also show that H‐1152 did not change either glial fibrillary acidic protein or isolectin‐B4 staining, indicating that this compound did not alter the cellular composition in our cultures. Thus, our data demonstrate that inhibition of Rho and its downstream effector ROCK may be used to enhance cell survival in neurodegenerative diseases. © 2007 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here